GM1 GANGLIOSIDOSIS TREATMENT MARKET ANALYSIS

GM1 Gangliosidosis Treatment Market, by Product Type (LYS-GM101, PBGM01, AXO-AAV-GM1), by Disease Type (Type 1 GM1 Gangliosidosis, Type 2 GM1 Gangliosidosis, and Type 3 GM1 Gangliosidosis), and by Region (North America, Europe and Rest of World ) - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2030

Published In : Nov 2020
Code : CMI4270
Pages :101
Formats :
Excel and PDF
Industry : Pharmaceutical

Gm1 Gangliosidosis Treatment MarketSize and Trends

The global GM1 gangliosidosis treatment market size is estimated to be valued at US$ 142.1 million in 2025 and is expected to exhibit a CAGR of 35.6 % during the forecast period (2025-2030).

Figure 1. Global GM1 Gangliosidosis Treatment Market Value (US$ Mn), 2025 - 2030

Market- Trends:

GM1 gangliosidosis is a rare central nervous system disorder and can develop throughout the lifetime in diagnosed individuals. For instance, in 2019, according to World Health Organization WHO data, around 2,000 patients suffer from GM1 ganglioside across the world. According to the same data source, incidence GM1 gangliosidosis accounts for around 0.5-1.0/100,000 births across the globe.